Last Updated: 12 Nov 2024
Executive Summary
Bluejay Diagnostics Inc. (BJDX) is a medical device company focused on developing and commercializing diagnostic tests for infectious diseases. The company has a strong pipeline of products in development, including tests for COVID-19, influenza, and other respiratory viruses. Bluejay Diagnostics has a market capitalization of $150.59 million and is traded on the NASDAQ exchange.
Company Overview
Bluejay Diagnostics was founded in 2015 and is headquartered in Acton, Massachusetts. The company's mission is to develop and commercialize diagnostic tests that are accurate, affordable, and easy to use. Bluejay Diagnostics' products are used in a variety of settings, including hospitals, clinics, and laboratories.
Fundamental Analysis
Bluejay Diagnostics is a pre-revenue company, so it does not have any revenue or earnings. The company's financial position is weak, with a negative EBITDA of -$87.38 million and a book value of $18.69 per share. Bluejay Diagnostics has a high level of debt, with a debt-to-equity ratio of 1.5.
Technical Analysis
The technical analysis of Bluejay Diagnostics' stock chart shows that the stock is in a downtrend. The stock has been making lower highs and lower lows since its peak in early 2021. The stock is currently trading below its 50-day and 200-day moving averages.
Short Term Outlook
The short-term outlook for Bluejay Diagnostics is negative. The stock is in a downtrend and is trading below its moving averages. The company's financial position is weak, and it is not expected to generate revenue in the near term.
Long Term Outlook
The long-term outlook for Bluejay Diagnostics is uncertain. The company has a strong pipeline of products in development, but it is not clear when these products will be commercialized. The company's financial position is weak, and it may need to raise additional capital in the future.
Analyst Recommendations
The majority of analysts have a hold rating on Bluejay Diagnostics. The average analyst target price is $256.00.
